29 related articles for article (PubMed ID: 7674118)
1. Designing reversible anticoagulants.
Crunkhorn S
Nat Rev Drug Discov; 2024 Jul; 23(7):499. PubMed ID: 38822114
[No Abstract] [Full Text] [Related]
2. Phenolic P2/P3 core motif as thrombin inhibitors--design, synthesis, and X-ray co-crystal structure.
Hanessian S; Therrien E; van Otterlo WA; Bayrakdarian M; Nilsson I; Fjellström O; Xue Y
Bioorg Med Chem Lett; 2006 Feb; 16(4):1032-6. PubMed ID: 16290930
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 2: N-acetamidoimidazoles.
Isaacs RC; Solinsky MG; Cutrona KJ; Newton CL; Naylor-Olsen AM; McMasters DR; Krueger JA; Lewis SD; Lucas BJ; Kuo LC; Yan Y; Lynch JJ; Lyle EA
Bioorg Med Chem Lett; 2008 Mar; 18(6):2062-6. PubMed ID: 18291642
[TBL] [Abstract][Full Text] [Related]
4. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
[TBL] [Abstract][Full Text] [Related]
5. Oxyguanidines. Part 2: Discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesis.
Lu T; Markotan T; Coppo F; Tomczuk B; Crysler C; Eisennagel S; Spurlino J; Gremminger L; Soll RM; Giardino EC; Bone R
Bioorg Med Chem Lett; 2004 Jul; 14(14):3727-31. PubMed ID: 15203151
[TBL] [Abstract][Full Text] [Related]
6. [A new generation of anticoagulants: design, synthesis and pharmacologic profile of thrombin inhibtors].
Schmid G; Ackermann J; Banner D; Gast A; Gubernator K; Hadváry P; Hilpert K; Labler L; Tschopp T
J Pharm Belg; 1995; 50(2-3):188-93. PubMed ID: 7674118
[No Abstract] [Full Text] [Related]
7. Pharmacologic aspects of the development of selective synthetic thrombin inhibitors as anticoagulants.
Hauptmann J; Markwardt F
Semin Thromb Hemost; 1992; 18(2):200-17. PubMed ID: 1631568
[No Abstract] [Full Text] [Related]
8. Novel anticoagulants based on direct inhibition of thrombin and factor Xa.
Gardell SJ; Sanderson PE
Coron Artery Dis; 1998; 9(2-3):75-81. PubMed ID: 9647407
[No Abstract] [Full Text] [Related]
9. Discovery of ximelagatran in an historical perspective.
Gustafsson D
Semin Vasc Med; 2005 Aug; 5(3):227-34. PubMed ID: 16123909
[TBL] [Abstract][Full Text] [Related]
10. Synthetic thrombin inhibitors as anticoagulants pharmacological aspects.
Markwardt F; Hauptmann J
Adv Exp Med Biol; 1993; 340():143-71. PubMed ID: 8154331
[No Abstract] [Full Text] [Related]
11. New antithrombotic drugs.
Gross PL; Weitz JI
Clin Pharmacol Ther; 2009 Aug; 86(2):139-46. PubMed ID: 19553932
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
